Form 4: Illumina Director Scott Ullem Granted Restricted Stock Units, Boosting Equity Stake

Illumina, Inc. Director Scott B. Ullem received a grant of 3,780 restricted stock units, increasing his total beneficial ownership in the company to 7,830 shares.

Summary

• Scott B. Ullem, a Director of Illumina, Inc. (ILMN), was granted 3,780 shares of common stock in the form of restricted stock units (RSUs) on May 21, 2025.
• The grant price for these RSUs was $0, which is typical for such equity awards.
• Following this transaction, Mr. Ullem's total beneficial ownership of Illumina common stock stands at 7,830 shares.
• The restricted stock units are set to vest 100% on the earlier of (i) the one-year anniversary of the grant date (May 21, 2026) or (ii) the date immediately preceding the company's annual stockholders' meeting for the year following the grant year, provided Mr. Ullem continues to serve as a director.

Sentiment

Score: 7

Explanation: The document reports a routine equity grant to a director, which is generally viewed positively as it aligns the director's interests with shareholders. There are no negative implications or unexpected events reported.

Positives

• The grant of restricted stock units to a director aligns management's interests with those of the shareholders, as the value of the award is tied to the company's stock performance.
• The increase in beneficial ownership demonstrates continued commitment and confidence from a key board member in the company's future.

Future Outlook

The restricted stock units granted to Director Scott B. Ullem are subject to future vesting, contingent upon his continued service as a director. The vesting will occur on the earlier of the one-year anniversary of the grant date or the day before the company's annual meeting in the year following the grant.

Industry Context

Equity grants, such as restricted stock units, are a common form of compensation for directors and executives in the biotechnology and life sciences industry, including companies like Illumina. This practice is designed to incentivize long-term performance and align the interests of leadership with those of shareholders.

Comparison to Industry Standards

• The grant of restricted stock units to a director is a standard practice for compensating board members in publicly traded companies, particularly within the high-growth biotechnology and healthcare sectors, aligning their incentives with shareholder value creation.
• Companies like Thermo Fisher Scientific (TMO), Danaher Corporation (DHR), and Agilent Technologies (A) also commonly utilize equity-based compensation for their non-employee directors, often structured with vesting periods tied to continued service.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units to Scott B. Ullem, a Director of Illumina, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with shareholder returns, potentially encouraging decisions that enhance long-term stock value.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• The restricted stock units will vest according to the specified schedule, contingent on Scott B. Ullem's continued service as a director.

Key Dates

Keywords

Illumina, ILMN, Scott B. Ullem, Form 4, SEC filing, insider transaction, restricted stock units, equity grant, director compensation, beneficial ownership